ICU Medical, Director Sells $92,483 in Stock (ICUI)
ICU Medical, (NASDAQ:ICUI) Director Robert S. Swinney sold 1,475 shares of the company’s stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of $62.70, for a total value of $92,482.50. Following the completion of the transaction, the director now directly owns 16,715 shares of the company’s stock, valued at approximately $1,048,031. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of ICU Medical, from a “neutral” rating to an “outperform” rating in a research note on Thursday. They now have a $66.90 price target on the stock. Analysts at Raymond James upgraded shares of ICU Medical, from a “market perform” rating to an “outperform” rating in a research note on Tuesday, August 12th. They now have a $67.00 price target on the stock. They noted that the move was a valuation call.
Shares of ICU Medical, (NASDAQ:ICUI) traded up 0.46% during mid-day trading on Monday, hitting $63.44. The stock had a trading volume of 81,190 shares. ICU Medical, has a one year low of $54.00 and a one year high of $74.93. The stock has a 50-day moving average of $60.0 and a 200-day moving average of $59.71. The company has a market cap of $968.7 million and a price-to-earnings ratio of 26.37.
ICU Medical, (NASDAQ:ICUI) last issued its quarterly earnings data on Monday, August 11th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.34 by $0.04. The company had revenue of $78.70 million for the quarter, compared to the consensus estimate of $74.13 million. During the same quarter in the prior year, the company posted $0.48 earnings per share. The company’s quarterly revenue was up .1% on a year-over-year basis. On average, analysts predict that ICU Medical, will post $1.40 earnings per share for the current fiscal year.
ICU Medical, Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.